Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.62 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | GBA1 | P04062 | 5/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | CLK1 | P49759 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27149789 | 0.84 | GBA1 (0.56) | ALDH1A1CYP1A2CYP3A4CLK4CYP2D6 | |
| SCHEMBL19286343 | 0.79 | CYP1A2 (0.74) | ALDH1A1CYP1A2CYP3A4CLK4CYP2D6 | |
| SCHEMBL7278023 | 0.79 | MEN1 (0.87) | ALDH1A1CYP1A2CYP3A4CLK4CYP2D6 | |
| SCHEMBL31392415 | 0.78 | ALDH1A1 (0.72) | ALDH1A1TSHRADORA3MEN1KMT2A | |
| SCHEMBL20273653 | 0.78 | CYP1A2 (1.00) | ALDH1A1CYP1A2CYP3A4CLK4CYP2D6 | |
| SCHEMBL15289677 | 0.77 | TSHR (0.77) | ALDH1A1CYP1A2CYP3A4CLK4CYP2D6 | |
| SCHEMBL7278041 | 0.77 | GBA1 (0.71) | ALDH1A1CYP1A2CYP3A4CLK4CYP2D6 | |
| SCHEMBL18354345 | 0.76 | GBA1 (1.00) | ALDH1A1CYP1A2CYP3A4CLK4CYP2D6 | |
| SCHEMBL31061430 | 0.75 | ADORA3 (1.00) | ALDH1A1CYP1A2CYP3A4CLK4CYP2D6 | |
| SCHEMBL31392377 | 0.75 | ALDH1A1 (0.67) | ALDH1A1CYP2D6CYP2C19TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120091811-A | Integrin inhibitors and their use in combination with other agents | 普利安特治疗公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-118401521-A | Integrin inhibitors and their use in combination with other agents | 普利安特治疗公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4329755-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117615760-A | Extended dosage regimen for integrin inhibitors | 普利安特治疗公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| CN-115989235-A | Methods of treating respiratory diseases using amino acid compounds | 普利安特治疗公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-4146264-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022232838-A1 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | PLIANT THERAPEUTICS, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| EP-3952902-A1 | DOSAGE FORMS AND REGIMENS FOR AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | ALDH1A1 3323/4885CYP1A2 3772/4885CYP3A4 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.